← Back to Search

Janus Kinase (JAK) Inhibitor

Deucravacitinib 6 mg Daily for Psoriasis

Q: Is the current clinical trial open for new participant enrollment?

According to the details available on clinicaltrials.gov, this trial is currently seeking participants. The study was first listed on March 1st, 2024, and has been most recently revised on March 12th of the same year.

Q: What are the eligibility criteria for individuals who can participate in this medical research study?

Furthermore patients must have chronic <a href="https://www.withpower.com/clinical-trials/plaque-psoriasis">plaque psoriasis</a> for a minimum of six months prior to

Q: What is the current number of individuals involved in this clinical trial as participants?

Indeed, the information on clinicaltrials.gov confirms that patient recruitment is ongoing for this trial. The initial posting of the study was on March 1st, 2024, with the latest update made on March 12th, 2024. Enrollment targets include 20 patients from a single designated site.

Q: Are individuals aged 60 and above being sought for enrollment in this research study?

Applicants aged between 18 and 99 are eligible for this study. It is important to note that there are separate trials available specifically for individuals under 18 (22 trials) as well as those over the age of 65 (136 trials).

Phase < 1

Recruiting

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to week 24

Awards & highlights

Study Summary

This trial will test the effectiveness and safety of deucravactinib in treating nail psoriasis in 20 adult patients. Patients will take deucravacitinib daily for

Who is the study for?

Adults over 18 with chronic plaque psoriasis and nail psoriasis, who are in good health aside from their skin condition. Participants must not have used systemic therapies for psoriasis or biologics within specific time frames before the study starts and be willing to have photos taken of their nails.Check my eligibility

What is being tested?

The trial is testing Deucravacitinib, an oral medication, given at a dose of 6 mg daily to treat nail psoriasis. The study will follow twenty patients for 48 weeks, using assessments like the modified Nail Psoriasis Severity Index and photographs to track changes.See study design

What are the potential side effects?

While specific side effects aren't listed here, participants will be monitored for any adverse reactions due to taking Deucravacitinib throughout the nearly one-year-long study period.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to week 24

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to week 24

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in the modified Nail Psoriasis Severity Index (mNAPSI) compared to baseline

Side effects data

From 2022 Phase 3 trial • 220 Patients • NCT04167462

18%

Upper respiratory tract infection

Mouth ulceration

Nasopharyngitis

Pruritus

Headache

Folliculitis

Psoriasis

Cholecystitis

Gastroenteritis shigella

Gastroenteritis

Pharyngitis

Diabetes mellitus

Accidental overdose

Hepatobiliary procedural complication

Psoriatic arthropathy

100%

80%

60%

40%

20%

Study treatment Arm

Placebo Week 0 up to Week 16

BMS-986165 Week 0 up to Week 52

BMS-986165 Week 16 up to Week 52

Trial Design

1Treatment groups

Experimental Treatment

Group I: Deucravacitinib 6 mg DailyExperimental Treatment1 Intervention

All participants will receive 6 mg of deucravacitinib daily.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Deucravacitinib

2021

Completed Phase 4

~160

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,590 Previous Clinical Trials

2,281,642 Total Patients Enrolled

7 Trials studying Psoriasis

40,662 Patients Enrolled for Psoriasis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the current clinical trial open for new participant enrollment?

"According to the details available on clinicaltrials.gov, this trial is currently seeking participants. The study was first listed on March 1st, 2024, and has been most recently revised on March 12th of the same year."

Answered by AI

What are the eligibility criteria for individuals who can participate in this medical research study?

"Furthermore patients must have chronic plaque psoriasis for a minimum of six months prior to"

Answered by AI

What is the current number of individuals involved in this clinical trial as participants?

"Indeed, the information on clinicaltrials.gov confirms that patient recruitment is ongoing for this trial. The initial posting of the study was on March 1st, 2024, with the latest update made on March 12th, 2024. Enrollment targets include 20 patients from a single designated site."

Answered by AI

Are individuals aged 60 and above being sought for enrollment in this research study?

"Applicants aged between 18 and 99 are eligible for this study. It is important to note that there are separate trials available specifically for individuals under 18 (22 trials) as well as those over the age of 65 (136 trials)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis

Boni Elewski 2024. "An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05124080.

All > Psoriasis